EXEL vs. SOLV: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EXEL and SOLV, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | EXEL | SOLV |
|---|---|---|
| Company Name | Exelixis, Inc. | Solventum Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 11.57 billion USD | 13.20 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | April 17, 2000 | March 26, 2024 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of EXEL and SOLV by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EXEL | SOLV |
|---|---|---|
| 5-Day Price Return | 0.58% | 5.39% |
| 13-Week Price Return | 8.72% | 5.94% |
| 26-Week Price Return | 12.72% | 2.91% |
| 52-Week Price Return | 18.36% | 8.02% |
| Month-to-Date Return | 7.71% | 9.59% |
| Year-to-Date Return | 25.08% | 14.53% |
| 10-Day Avg. Volume | 3.18M | 1.29M |
| 3-Month Avg. Volume | 2.91M | 1.03M |
| 3-Month Volatility | 39.61% | 26.54% |
| Beta | 0.39 | 0.92 |
Profitability
Return on Equity (TTM)
EXEL
31.64%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
In the upper quartile for the Biotechnology industry, EXEL’s Return on Equity of 31.64% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
SOLV
41.02%
Health Care Equipment & Supplies Industry
- Max
- 29.82%
- Q3
- 15.54%
- Median
- 9.69%
- Q1
- 5.19%
- Min
- -7.98%
SOLV’s Return on Equity of 41.02% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
EXEL
29.63%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
A Net Profit Margin of 29.63% places EXEL in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
SOLV
18.13%
Health Care Equipment & Supplies Industry
- Max
- 24.65%
- Q3
- 14.10%
- Median
- 10.09%
- Q1
- 5.84%
- Min
- -6.13%
A Net Profit Margin of 18.13% places SOLV in the upper quartile for the Health Care Equipment & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
EXEL
34.97%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
An Operating Profit Margin of 34.97% places EXEL in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
SOLV
25.11%
Health Care Equipment & Supplies Industry
- Max
- 31.34%
- Q3
- 18.36%
- Median
- 15.07%
- Q1
- 9.62%
- Min
- -0.13%
An Operating Profit Margin of 25.11% places SOLV in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | EXEL | SOLV |
|---|---|---|
| Return on Equity (TTM) | 31.64% | 41.02% |
| Return on Assets (TTM) | 24.03% | 10.50% |
| Net Profit Margin (TTM) | 29.63% | 18.13% |
| Operating Profit Margin (TTM) | 34.97% | 25.11% |
| Gross Profit Margin (TTM) | 96.63% | 54.18% |
Financial Strength
Current Ratio (MRQ)
EXEL
3.75
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
EXEL’s Current Ratio of 3.75 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
SOLV
1.50
Health Care Equipment & Supplies Industry
- Max
- 4.97
- Q3
- 2.92
- Median
- 2.12
- Q1
- 1.54
- Min
- 0.86
SOLV’s Current Ratio of 1.50 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
EXEL
0.00
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
EXEL’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
SOLV
1.03
Health Care Equipment & Supplies Industry
- Max
- 1.62
- Q3
- 0.74
- Median
- 0.47
- Q1
- 0.15
- Min
- 0.00
SOLV’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 1.03. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
EXEL
42.74
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
EXEL’s Interest Coverage Ratio of 42.74 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
SOLV
2.65
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 24.86
- Median
- 9.84
- Q1
- 3.86
- Min
- -21.65
In the lower quartile for the Health Care Equipment & Supplies industry, SOLV’s Interest Coverage Ratio of 2.65 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
Financial Strength at a Glance
| Symbol | EXEL | SOLV |
|---|---|---|
| Current Ratio (MRQ) | 3.75 | 1.50 |
| Quick Ratio (MRQ) | 3.47 | 1.14 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 1.03 |
| Interest Coverage Ratio (TTM) | 42.74 | 2.65 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EXEL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXEL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
SOLV
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.36%
- Q3
- 1.87%
- Median
- 0.82%
- Q1
- 0.00%
- Min
- 0.00%
SOLV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
EXEL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXEL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
SOLV
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 67.77%
- Median
- 28.21%
- Q1
- 0.00%
- Min
- 0.00%
SOLV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | EXEL | SOLV |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
EXEL
16.96
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
EXEL’s P/E Ratio of 16.96 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
SOLV
8.68
Health Care Equipment & Supplies Industry
- Max
- 67.59
- Q3
- 41.41
- Median
- 33.11
- Q1
- 22.82
- Min
- 8.68
In the lower quartile for the Health Care Equipment & Supplies industry, SOLV’s P/E Ratio of 8.68 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
EXEL
5.02
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
EXEL’s P/S Ratio of 5.02 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
SOLV
1.57
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.92
- Q1
- 1.97
- Min
- 0.61
In the lower quartile for the Health Care Equipment & Supplies industry, SOLV’s P/S Ratio of 1.57 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
EXEL
4.99
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
EXEL’s P/B Ratio of 4.99 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
SOLV
2.54
Health Care Equipment & Supplies Industry
- Max
- 10.77
- Q3
- 6.04
- Median
- 3.32
- Q1
- 2.31
- Min
- 0.83
SOLV’s P/B Ratio of 2.54 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | EXEL | SOLV |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 16.96 | 8.68 |
| Price-to-Sales Ratio (TTM) | 5.02 | 1.57 |
| Price-to-Book Ratio (MRQ) | 4.99 | 2.54 |
| Price-to-Free Cash Flow Ratio (TTM) | 14.74 | 57.46 |